Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Preeclampsia
100%
Pregnant Women
75%
COVID-19
55%
Indonesia
48%
High-risk Pregnancy
28%
Early Detection
25%
COVID-19 Infection
24%
Perinatal Outcome
23%
Maternal Outcomes
23%
Surabaya
23%
Soluble Fms-like Tyrosine kinase-1 (sFlt-1)
22%
Early Onset
19%
Placenta
17%
High Risk
16%
Maternal Morbidity
15%
During Pregnancy
15%
Atorvastatin
15%
Dempster-Shafer Method
15%
Magnesium Sulfate
15%
Neonatal Death
15%
Rapid Antigen Test
15%
Expert System
15%
COVID-19 Pandemic
15%
Wound Healing
15%
Placenta Accreta Spectrum
15%
Cardiovascular Risk
15%
Early-onset Preeclampsia
15%
Cesarean Delivery
14%
Neonatal Morbidity
14%
Confidence Interval
14%
Mode of Delivery
13%
Obstetrics
13%
Serum Levels
12%
Late-onset Preeclampsia
12%
Late-onset
12%
Treatment Group
12%
Risk Ratio
12%
Inclusion Criteria
11%
Antibody Test
11%
Neonatal Mortality
10%
Neonatal Outcome
10%
Quantitative PCR
10%
Obstetrics and Gynaecology
10%
Tertiary Referral Hospital
10%
Preeclampsia with Severe Features
10%
Magnesium
9%
General Hospital
9%
2-Methoxyethanol
9%
COVID-19 Cases
9%
Non-COVID-19
9%
Medicine and Dentistry
Pre-Eclampsia
89%
COVID-19
61%
Infection
23%
Obstetrics
21%
Patient Referral
20%
Placenta Accreta
18%
Immunoassay
16%
Newborn Death
15%
Obstetric Emergency
15%
Cardiovascular Risk
15%
Magnesium Sulfate
15%
Magnesium
15%
Maternal Morbidity
13%
Placenta
12%
Premature Labor
11%
Diseases
10%
Cross Sectional Study
10%
Newborn Mortality
10%
Newborn Morbidity
10%
Gestational Age
10%
Obesity
10%
Randomized Controlled Trial
9%
Cohort Analysis
8%
Lymphocyte
8%
Cesarean Section
8%
Body Mass Index
8%
Prematurity
8%
Gynecology
8%
Gestational Diabetes
8%
Patient with Obesity
7%
Maternal Diabetes Mellitus
7%
Pregnancy
7%
Diabetes
7%
Pravastatin
7%
Polypharmacy
7%
Health Care
7%
Fetus Growth
7%
Platelet
7%
Antihypertensive Agent
7%
Analgesia
7%
Spectrum Disorder
7%
Health Care Management
7%
Meta-Analysis
7%
Systematic Review
7%
Wound Healing
7%
Heart Disease
7%
Health Service
7%
Maternal Welfare
7%
Pericarp
7%
Nifedipine
7%
Pharmacology, Toxicology and Pharmaceutical Science
Preeclampsia
64%
Maternal Mortality
30%
Infection
24%
Treatment Group
16%
Pravastatin
15%
High Risk Pregnancy
15%
Magnesium Sulfate
15%
Obesity
12%
SARS Coronavirus
11%
Maternal Morbidity
11%
Maternal Death
10%
Diabetes Mellitus
10%
2 Methoxyethanol
10%
Mortality Rate
10%
Cross-Sectional Study
9%
Randomized Controlled Trial
9%
Cohort Study
8%
Newborn Morbidity
8%
Hyaline Membrane Disease
8%
Prematurity
8%
Perinatal Morbidity
8%
Newborn Mortality
8%
Premature Labor
7%
Hemoglobins
7%
Toxic Injury
7%
Clinical Trial
7%
Placenta Accreta
7%
Protein Tyrosine Kinase
7%
Nifedipine
7%
Antihypertensive Agent
7%
Pregnancy Diabetes Mellitus
7%
Maternal Diabetes Mellitus
7%
Placental Growth Factor
7%
Heart Disease
7%
Wound Healing
7%
Hemoglobin A1c
7%
Xanthone Derivative
7%
Garcinia mangostana
7%
Tablet
7%
Iron
7%
Mouse Model
7%
Dysmenorrhea
7%
Curcumin
7%
Perinatal Mortality
7%
Placenta Previa
6%
Methylprednisolone
6%
Antihypertensive Drug
5%
Methyldopa
5%
Inflammation
5%